ETHE1: The Protein expressed in Thyroid that Could be a Drug Target or Biomarker

Target Name: ETHE1

NCBI ID: G23474

ETHE1

ETHE1: The Protein expressed in Thyroid that Could be a Drug Target or Biomarker

Thyroid is a crucial gland that plays a vital role in the body, regulating metabolism and growth. It is also responsible for producing thyroid hormones, which help regulate various bodily functions. One of the proteins expressed in the thyroid gland that has gained significant attention in recent years is ETHE1.

ETHE1, or thyroid-stimulating hormone receptor alpha, is a protein that is expressed in the thyroid gland and has been identified as a potential drug target or biomarker. The ETHE1 protein is a transmembrane protein that is composed of two extracellular domains and an intracellular domain.

The intracellular domain of the ETHE1 protein contains a potential N-terminus that could be involved in ligand binding, a process that is known to play a crucial role in protein-protein interactions and may be involved in the regulation of cellular processes such as cell signaling and intracellular signaling cascades.

The ETHE1 protein is also known to be involved in the regulation of gene expression in the thyroid gland. Studies have shown that the ETHE1 protein can interact with various transcription factors, including T-DNA, to regulate gene expression. This suggests that the ETHE1 protein may be involved in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

In addition to its potential role in gene expression, the ETHE1 protein has also been shown to play a role in the regulation of cellular signaling pathways. Studies have shown that the ETHE1 protein can interact with various signaling molecules, including hormones, to regulate cellular signaling pathways. This suggests that the ETHE1 protein may be involved in the regulation of cellular processes such as cell signaling, cell division, and apoptosis.

The ETHE1 protein is also of interest as a potential biomarker in thyroid diseases. Thyroid diseases are a common condition that affect millions of people worldwide, including Graves' disease and hyperthyroidism. The ETHE1 protein has been shown to be expressed in the thyroid gland and has has been suggested as a potential biomarker for thyroid diseases. Studies have shown that the ETHE1 protein can be used as a marker for the diagnosis and monitoring of thyroid diseases, including Graves' disease and hyperthyroidism.

In addition to its potential role in drug targeting and biomarker, the ETHE1 protein has also been shown to have potential therapeutic applications. Studies have shown that inhibiting the ETHE1 protein can be effective in treating thyroid diseases, including Graves' disease and hyperthyroidism. This suggests that the ETHE1 protein may be a promising target for new thyroid disease therapies.

In conclusion, the ETHE1 protein is a protein that is expressed in the thyroid gland and has potential as a drug target or biomarker. Its involvement in the regulation of cellular processes such as cell signaling, cell growth, apoptosis, and inflammation, as well as its role in the regulation of gene expression and the regulation of thyroid diseases, make it an attractive target for further research. Further studies are needed to fully understand the potential therapeutic applications of the ETHE1 protein and its role in the regulation of cellular processes in the thyroid gland.

Protein Name: ETHE1 Persulfide Dioxygenase

Functions: Sulfur dioxygenase that plays an essential role in hydrogen sulfide catabolism in the mitochondrial matrix. Hydrogen sulfide (H(2)S) is first oxidized by SQRDL, giving rise to cysteine persulfide residues. ETHE1 consumes molecular oxygen to catalyze the oxidation of the persulfide, once it has been transferred to a thiophilic acceptor, such as glutathione (R-SSH). Plays an important role in metabolic homeostasis in mitochondria by metabolizing hydrogen sulfide and preventing the accumulation of supraphysiological H(2)S levels that have toxic effects, due to the inhibition of cytochrome c oxidase. First described as a protein that can shuttle between the nucleus and the cytoplasm and suppress p53-induced apoptosis by sequestering the transcription factor RELA/NFKB3 in the cytoplasm and preventing its accumulation in the nucleus (PubMed:12398897)

The "ETHE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ETHE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets